Individualized Medication Guidance for Cancer (800 Genes) CapitalBio

Name: Individualized Medication Guidance for Cancer (800 Genes)
Brand: CapitalBiotech Co., Ltd.

This test detects 800 genes related to targeted therapy, chemotherapy, endocrine therapy, hereditary tumors, immunotherapy-related markers (MSI and TMB), core tumor signaling pathways, and tumor prognosis. The types of variants detected include SNVs, InDels, amplifications and gene fusions, to assist healthcare providers in formulating professional and individualized treatment plans for patients.

Inquire Now

Features of Individualized Medication Guidance for Cancer (800 Genes)

Applicable Population of Individualized Medication Guidance for Cancer (800 Genes)

Patients with locally advanced or metastatic tumors looking for targeted therapy.
Patients with locally advanced or metastatic solid tumors considering immunotherapy, where no definitive driver genes been diagnosed.
Patients with locally advanced or metastatic solid tumors undergoing targeted therapy or immunotherapy, requiring dynamic monitoring of treatment through NGS.

Specification of Individualized Medication Guidance for Cancer (800 Genes)

Sample types	Fresh tissue + venous blood; Paraffin specimen + venous blood; Venous blood
TAT	10 working days

Products

Related Solutions for Anti-cancer Therapy

Breast Cancer Prognosis Assessment

Targeted Medication Guidance for Lung Cancer

Related Solutions for Anti-cancer Therapy Documents

Respiratory Pathogenic Bacteria Nucleic Acid Test Kit Brochure

Click To View

M.Tuberculosis Drug Resistance Detection Array Kit Brochure

Click To View

CapitalBiotech News & Blog

News

CapitalBiotech Continues to Promote the National Precision Medicine Center in Kyrgyzstan

25 Jun,2025

10

Jun 2025

CapitalBiotech's DNA Rapid Detection System Shines at Securex South Africa 2025 NEWS

29

Apr 2025

Advantages of NGS Genetic Testing NEWS

22

Apr 2025

A Brief Analysis of Microfluidic Technology NEWS